Children's & Adolescent Health • ICD-10-CM P07.8
Sudden Infant Death Syndrome
Also known as: Crib death, SIDS
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM P07.8 • 6 Linked .gov / PubMed Citations
•
Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Sudden Infant Death Syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Sudden infant death syndrome (SIDS) is the sudden, unexplained death of an infant younger than one year old.
- 2 Real-world patient consensus: Diagnostic registry P07.8: Sudden Infant Death Syndrome is managed within Pediatrics (aka Crib death).
- 3 Typical cash cost range: Differential triage of Sudden Infant Death Syndrome (P07.8) utilizes immunization schedule review [Sudden Infant Death Syndrome P07.8].
- 4 Top reported side effects / signs: Objective lab/clinical target for Sudden Infant Death Syndrome: Pediatric Hemoglobin & in Sudden Infant Death Syndrome (P07.8: Lead Screen) (Age-normal hemoglobin; blood lead < 3.5 mcg/dL (P07.8)) and WHO / CDC in Sudden Infant Death Syndrome (P07.8: Age-Adjusted Growth Percentiles).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Sudden Infant Death Syndrome
What Is Sudden Infant Death Syndrome?
Sudden infant death syndrome (SIDS) is the sudden, unexplained death of an infant younger than one year old. Some people call SIDS "crib death" because many babies who die of SIDS are found in their cribs. SIDS is the leading cause of death in children between one month and one year old. Most SIDS deaths occur when babies are between one month and four months old. Premature babies, boys, African Americans, and American Indian/Alaska Native infants have a higher risk of SIDS. Although the cause of SIDS is unknown, there are steps you can take to reduce the risk. These include: Placing your baby on his or her back to sleep, even for short naps.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Sudden Infant Death Syndrome (ICD-10 P07.8) is driven by rapid somatic [Sudden Infant Death Syndrome P07.8]; Cross-referenced with NIH MeSH (Sudden Infant Death), specialists in Children's & Adolescent Health monitor WHO / CDC in Sudden Infant Death Syndrome (P07.8: Age-Adjusted Growth Percentiles) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Placing your baby on his or her back to sleep, even for short naps. "Tummy time" is for when babies are awake and someone is watching
- • Using a firm sleep surface, such as a crib mattress covered with a fitted sheet
- • Presentation of Sudden Infant Death Syndrome (P07.8): developmental milestone questions in Sudden Infant Death Syndrome (P07.8: across speech, motor)
- • Secondary Sudden Infant Death Syndrome clinical sign: pediatric skin rashes, in Sudden Infant Death Syndrome (P07.8: gastrointestinal discomfort, or)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sudden Infant Death Syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | P07.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Sudden Infant Death Syndrome (P07.8: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (P07.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: WHO / CDC in Sudden Infant Death Syndrome (P07.8: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (P07.8) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Sudden Infant Death Syndrome
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nivolumab Opdivo • RxCUI RXN-00033756-2313 | Programmed Death Receptor-1 Blocking Antibody | 78% | $1.5200 | $ 70.06 /mo |
| Nivolumab and Relatlimab-Rmbw Opdualag • RxCUI RXN-00037125-3208 | Programmed Death Receptor-1 Blocking Antibody | 78% | $0.8000 | $ 40.90 /mo |
| Keytruda Qlex (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Keytruda Qlex • RxCUI RXN-B00063083 | Programmed Death Receptor-1 Blocking Antibody | 86% | $0.6600 | $ 56.02 /mo |
| Cosibelimab Unloxcyt • RxCUI RXN-70095130-2813 | Programmed Death Ligand-1 Blocker | 74% | $0.3000 | $ 20.65 /mo |
| Tevimbra (Tislelizumab-Jsgr) Tevimbra • RxCUI RXN-B72579121 | Programmed Death Receptor-1 Blocking Antibody | 84% | $3.0600 | $ 228.82 /mo |
| Sotagliflozin Inpefa • RxCUI 2638683 | Sodium-Glucose Cotransporter 2 Inhibitor | 94% | $20.3408 | $ 185.00 /mo |
| Ticagrelor Brilinta • RxCUI 1116635 | P2Y12 Platelet Inhibitor | 81% | $0.2429 | $ 10.64 /mo |
| Sacubitril and Valsartan Entresto • RxCUI 1656349 | Angiotensin 2 Receptor Blocker | 91% | $0.5265 | $ 29.82 /mo |
| Opdualag (Nivolumab and Relatlimab-Rmbw) Opdualag • RxCUI RXN-B00037125 | Programmed Death Receptor-1 Blocking Antibody | 75% | $0.6700 | $ 56.74 /mo |
| Jemperli (Dostarlimab) Jemperli • RxCUI RXN-B01730898 | Programmed Death Receptor-1 Blocking Antibody | 85% | $0.9500 | $ 76.90 /mo |
| Keytruda (Pembrolizumab) Keytruda • RxCUI RXN-B00063026 | Programmed Death Receptor-1 Blocking Antibody | 74% | $1.0700 | $ 85.54 /mo |
| Nivolumab and Hyaluronidase-Nvhy Opdivo Qvantig • RxCUI 2700798 | Programmed Death Receptor-1 Blocking Antibody | 86% | $2.6100 | $ 114.20 /mo |
| Toripalimab-Tpzi Loqtorzi • RxCUI RXN-70114340-2583 | Programmed Death Receptor-1 Blocking Antibody | 79% | $1.4600 | $ 67.63 /mo |
| Imfinzi (Durvalumab) Imfinzi • RxCUI RXN-B03104611 | Programmed Death Ligand-1 Blocker | 77% | $1.3500 | $ 105.70 /mo |
| Atezolizumab Tecentriq • RxCUI RXN-50242917-2521 | Programmed Death Receptor-1 Blocking Antibody | 88% | $1.4300 | $ 66.41 /mo |
| Durvalumab Imfinzi • RxCUI RXN-03104611-2881 | Programmed Death Ligand-1 Blocker | 94% | $1.9300 | $ 86.67 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sudden Infant Death Syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Obstructive sleep apnea and the risk of sudden cardiac Available evidence is insufficient to establish a definitive association between OSA and SCD. BMC cardiovascular disorders • 2025-10-21 • Meta-Analysis | Multi-cohort | 86/100 | PMID 41120867 ↗ |
| Managing Obstructive sleep apnoea: Can Sudden death Make a Real Difference? (What New Research Reveals) OSA is a significant risk factor for all-cause mortality and cardiac mortality. BMJ open respiratory research • 2021-06-15 • Meta-Analysis | N = 42 | 86/100 | PMID 34108135 ↗ |
| Can This Approach Help? Inside the Latest Research on Open-Label Dose Optimization of Methylphenidate Extended-Release Orally AEs were consistent with those of other MPH products. Journal of child and adolescent psychopharmacology • 2021-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34081560 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Sudden Infant Death Syndrome Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Sudden Infant Death Syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Sudden Infant Death Syndrome.